> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 13 Observations in Akorn Inspection FDA-483
- URL: https://www.fdaweb.com/13-observations-in-akorn-inspection-fda-483/
- Published: 2018-07-19T12:00:00.000Z
- Updated: 2026-09-15T00:20:32.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5141917

FDA has released the FDA-483 issued following a 4/9-5/18 inspection at Akorn, a sterile drug manufacturer in Decatur, IL. Specific observations in the document [were](https://www.fda.gov/AboutFDA/CentersOffices/OfficeofGlobalRegulatoryOperationsandPolicy/ORA/ORAElectronicReadingRoom/UCM613670?ref=fdaweb.com): 

- failing to establish and follow appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including validation of all aseptic and sterilization processes;
- failing to establish an adequate system for monitoring environmental conditions in aseptic processing areas;
- failing to include in an annual report a full description of the manufacturing and control changes not requiring a supplemental application, listed by date in the order in which they were implemented;
- failing to establish an adequate system for cleaning and disinfecting the room and equipment used to produce aseptic conditions;
- failing to maintain complete data derived from all testing and to ensure compliance with established specifications and standards pertaining to data retention and management;
- failing to submit an NDA-Field Alert Report within three working days of receiving information concerning bacteriological contamination and/or significant chemical, physical, or other change or deterioration in a distributed drug product;
- failing to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed;
- equipment used in the manufacture, processing, packing, or holding of drug products is not of appropriate design to facilitate operations for its intended use and cleaning and maintenance;
- failing to examine visually upon receipt and before acceptance of each container or grouping of containers of components for container damage, broken seals, or contamination;
- failing to have the written stability program for drug products include reliable, meaningful, and specific test methods;
- failing to establish control procedures that monitor the output of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product;
- employees engaged in the manufacture, processing, packing, and holding of a drug product lack the training required to perform their assigned functions; and
- failing to examine visually for evidence of deterioration at least once a year reserve samples from representative sample lots or batches of drug product selected by acceptable statistical procedures.